Evidence map›Paper›PMID 42547568›Full record

ArticleBritish journal of cancer2026

Super-enhancer landscape regulated by CDK12 drives retinoblastoma progression.

Caiyao Guo, Wei Dai, Jingxuan Li, Xuan Zhou, Jianqiong Yang, Fenfen Xie, Wan Liang, Jingfeng Zhou, Wen Hou, Jinxia Lan and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Caiyao Guo *Jiangxi Province Key Laboratory of Pharmacology of Traditional Chinese Medicine, Gannan Medical University, Ganzhou, China.
Wei Dai *Jiangxi Province Key Laboratory of Pharmacology of Traditional Chinese Medicine, Gannan Medical University, Ganzhou, China.
Jingxuan Li *School of Rehabilitation Medicine, Gannan Medical University, Ganzhou, China.
Xuan Zhou *Jiangxi Province Key Laboratory of Pharmacology of Traditional Chinese Medicine, Gannan Medical University, Ganzhou, China.
Jianqiong YangGanzhou Key Laboratory of Antitumor Effects of Natural Products, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
Fenfen XieJiangxi Province Key Laboratory of Pharmacology of Traditional Chinese Medicine, Gannan Medical University, Ganzhou, China.
Wan LiangJiangxi Province Key Laboratory of Pharmacology of Traditional Chinese Medicine, Gannan Medical University, Ganzhou, China.
Jingfeng ZhouInternational Cancer Center, Department of Hematology and Oncology, Hematology Institution of Shenzhen University, Shenzhen University General Hospital, Department of Pharmacology, School of Basic Medical Sciences, Shenzhen University Health Science Center, Shenzhen University, Shenzhen, China.
Wen HouJiangxi Province Key Laboratory of Pharmacology of Traditional Chinese Medicine, Gannan Medical University, Ganzhou, China.
Jinxia LanCollege of Public Health and Health Management, Gannan Medical University, Ganzhou, China.
Hai LiuJiangxi Province Key Laboratory of Pharmacology of Traditional Chinese Medicine, Gannan Medical University, Ganzhou, China.
Shenglan LiuJiangxi Province Key Laboratory of Pharmacology of Traditional Chinese Medicine, Gannan Medical University, Ganzhou, China. liushl5@gmu.edu.cn.ORCID http://orcid.org/0000-0002-7306-7922

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82260718National Natural Science Foundation of China (National Science Foundation of China) 82460716Natural Science Foundation of Jiangxi Province (Jiangxi Province Natural Science Foundation) 20232BAB216137;20252BAC240506Natural Science Foundation of Jiangxi Province (Jiangxi Province Natural Science Foundation) 20242BAB25579
6 · The paper itself

Abstract

backgroundRetinoblastoma (RB) lacks effective targeted therapies. Super-enhancers (SEs) are crucial for tumorigenesis, yet their role in RB was unclear.

methodsWe profiled active SEs in RB cells using chromatin immunoprecipitation sequencing (ChIP-Seq) and RNA sequencing (RNA-Seq). qRT-PCR, single-cell RNA sequencing (scRNA-Seq) and immunohistochemistry (IHC) were employed to identify the critical regulator of SE activity. The anti-tumour effect of targeted blockade of SE regulator, achieved via pharmacological degradation and specific lentiviruses, was investigated in vitro and in preclinical models of subcutaneous, intraocular, and central nervous system (CNS)-metastatic RB.

resultsCyclin-dependent kinase 12 (CDK12) was identified as a key SE regulator. SE-driven oncogenic transcription was suppressed by CDK12 inhibition, leading to eliminated tumour outgrowth and metastasis. In addition, SE-associated oncogenes BIRC5 and PTPRC were identified as essential for RB cell survival and stemness. Furthermore, PTPRC overexpression rescued the anti-tumour effect of BSJ-4-116.

conclusionsThis study defines CDK12 as a master regulator of oncogenic SEs in RB. Targeting the CDK12-SE axis, via CDK12 or downstream effectors like BIRC5/PTPRC, presents a novel therapeutic strategy.

Identifiers

PMID42547568

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.